CYP2C19Your two copies: *1/*2
Intermediate metabolizer
One copy works and one doesn't.
Handles several SSRIs, acid reducers such as omeprazole, and the blood thinner clopidogrel.
This result changes the label.
Example report. Made from Leslie Knope's DNA data so you can see what yours will look like. Get your own report
Proton pump inhibitorsExample report
Dexlansoprazole
Dexilant
Use with caution
Your body clears this drug more slowly. A lower dose may be needed for long-term use to prevent side effects.
The genes behind this label
The guidelines read one gene for dexlansoprazole. Each card shows the two copies this person inherited and what they mean.
What the guidelines say
What each guideline says about your result.
CYP2C19Intermediate metabolizer
CPIC guideline
Evidence: optionalRead the guideline (Clinical Pharmacogenetics Implementation Consortium, opens in a new tab)
- In plain words
- Your body clears this drug more slowly. A lower dose may be needed for long-term use to prevent side effects.
- What it means
- Increased plasma concentration of PPI compared with CYP2C19 normal metabolizers; increased chance of efficacy and potentially toxicity
- What the guideline suggests
- Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.
About dexlansoprazole
Dexlansoprazole (Dexilant) is a proton pump inhibitor (PPI) for erosive esophagitis and heartburn from reflux, approved for people 12 and older.
- Used for
- Healing erosive esophagitis, keeping it healed and relieving heartburn, and symptomatic non-erosive reflux disease, in people 12 and older
Others in proton pump inhibitors
Compare all 4 proton pump inhibitorsDon't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.